Silverarc Capital Management’s CTI BioPharma Corp. (DE) Common Stock CTIC Stock Holding History

Silverarc Capital Management’s Portfolio CTIC Stock Details CTIC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-254,361	Closed	-$1.53M	–	111
2022 Q4	$1.53M	Sell	254,361 -729,155	-74%	-$3.98M	0.44%	58
2022 Q3	$5.72M	Sell	983,516 -396,595	-29%	-$2.47M	1.94%	22
2022 Q2	$8.24M	Sell	1,380,111 -869,889	-39%	-$4.45M	2.54%	12
2022 Q1	$10.5K	Buy	2,250,000 +766,171	+52%	+$2.29M	4.35%	6
2021 Q4	$3.68M	Buy	+1,483,829	New	+$3.63M	1.49%	21

Other funds holding CTIC

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

RCMNY

Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

SCM

Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BCLSI

Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return

Bleichroeder LP New York $579M AUM 94.36% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

Silverarc Capital Management's CTIC Position: Q1 2023 in Review

Silverarc Capital Management sold out of CTI BioPharma Corp. (DE) Common Stock (CTIC) in Q1 2023, closing a stake of 254,361 shares — an estimated $1.53M sold.

Silverarc Capital Management first reported a position in CTIC in Q4 2021 and held it in 5 quarters. The position peaked at $8.24M in Q2 2022. 133 funds tracked by Wall St. Rank hold CTIC as of Q1 2023.

Silverarc Capital Management reported no remaining CTI BioPharma Corp. (DE) Common Stock position as of Q1 2023 after selling out during the quarter.
Silverarc Capital Management sold 254,361 CTI BioPharma Corp. (DE) Common Stock shares in Q1 2023, an estimated $1.53M.
Silverarc Capital Management first reported a position in CTI BioPharma Corp. (DE) Common Stock in Q4 2021 and held it in 5 quarters.
Silverarc Capital Management's CTI BioPharma Corp. (DE) Common Stock position peaked at $8.24M in Q2 2022.
133 funds tracked by Wall St. Rank held CTI BioPharma Corp. (DE) Common Stock as of Q1 2023.

Based on Silverarc Capital Management's 13F filing for Q1 2023, filed 15 May 2023.